JAK2 and myelofibrosis: Momelotinib, an inhibitor of JAK1, JAK2, and ACVR1, was approved in 2023 for the treatment of patients with myelofibrosis and anemia [25] and has shown spleen and symptom benefits in phase 3 trials in this patient population [26, 27, 28].